The independent source for health policy research, polling, and news.
KFF’s policy research provides facts and analysis on a wide range of policy issues and public programs.
KFF designs, conducts and analyzes original public opinion and survey research on Americans’ attitudes, knowledge, and experiences with the health care system to help amplify the public’s voice in major national debates.
KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the organization’s core operating programs.
A summary of key provisions of the Families First Coronavirus Response Act that addresses the domestic coronavirus outbreak, including paid sick leave, insurance coverage of coronavirus testing, nutrition assistance, and unemployment benefits.
In response to prescription drug spending growth and heightened attention to drug prices, some policymakers have proposed allowing the federal government to negotiate the price of prescription drugs for Medicare and private payers. This brief describes the current status of drug price negotiation proposals, looks back at the history of proposals to give the federal government the authority to negotiate drug prices in Medicare, describes the negotiation provisions in key legislation (H.R. 3), and discusses the potential spending effects for the federal government, beneficiaries, and private payers.
On May 28th, President Biden will release his first detailed budget proposal, covering the fiscal year starting in October 2021. As the largest global health donor in the world, the new budget proposal will provide a glimpse into what the Biden administration will be prioritizing for global health.
To provide context for the release of the administration’s first, full budget request for FY 2022, this brief provides an overview of historical trends in U.S. global health funding, including changes in program-specific funding over time, the distribution between bilateral and multilateral support, and in the increasing use of emergency supplemental funding in response to outbreaks.
This data note examines the status of U.S. global COVID-19 country, regional, and worldwide funding to assess how much has been committed to date and where it has been directed.
Earlier this week, the Biden Administration announced the final Medicare Advantage rates for 2023, which are projected to result in an average increase in Medicare Advantage plan revenue of 8.5% compared to 2022 - the highest average expected increase in recent years.
A current impasse in Congress threatens continued funding for COVID-19 testing, treatment, and vaccines. The lack of additional federal COVID-19 funding has broad implications for access to these services, particularly for the uninsured, and could undermine efforts to ensure equitable access to these resources.
The U.S. government is the largest donor to global health in the world. This fact sheet breaks down the U.S. global health budget by program area: HIV/PEPFAR; tuberculosis; malaria/the President's Malaria Initiative; the Global Fund to Fight AIDS, Tuberculosis, and Malaria; maternal & child health; nutrition; family planning & reproductive health; global health security; and neglected tropical diseases.
In a Health Affairs blog post, Jen Kates and Adam Wexler of the Kaiser Family Foundation and Nafis Sadat and Joseph Dieleman of the Institute for Health Metrics and Evaluation assess what cuts to
The federal government spent $321 more per person for beneficiaries enrolled in Medicare Advantage plans than for those in traditional Medicare in 2019, a gap that amounted to $7 billion in additional spending on the increasingly popular private plans that year, finds a new KFF analysis.
© 2026 KFF